Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 14Gynecologic 7Dermatologic 7Head & Neck 6Genitourinary 6Thoracic 5Gastrointestinal 4Sarcoma 2Other solid neoplasm 2Lymphoid 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 5Carcinoma, Neuroendocrine 5Thyroid Neoplasms 2Adrenocortical Carcinoma 2Vulvar Neoplasms 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Small Cell Lung Carcinoma 1Seminoma 1Sarcoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Pituitary Neoplasms 1Pituitary Diseases 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Penile Neoplasms 1Parathyroid Neoplasms 1Paranasal Sinus Neoplasms 1Paraganglioma 1Paget Disease, Extramammary 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Histiocytoma, Malignant Fibrous 1

Interventions

Nivolumab 2spartalizumab 1regorafenib 1fludarabine 1aldesleukin 1Ipilimumab 1IPI-549 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Ipilimumab × Endocrine × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡